Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity
作者： S Parmar , C Schumann , S Rüdiger , S Boeck , V Heinemann
DOI: 10.1038/TPJ.2011.51
关键词:
摘要: The aim of this study was to investigate pharmacogenetic determinants skin rash associated with epidermal growth factor receptor (EGFR) inhibitor treatment. A total 109 prospectively sampled cancer patients, receiving the first treatment an EGFR inhibitor, were genotyped for functional polymorphisms and tagging variants in genes involved downstream signaling. Skin absent 26 (23.9%) patients shorter overall survival compared presenting (P=0.005). polymorphisms, 497G/A (P=0.008), haplotypes promoter variants, EGFR-216G/T -191C/A (P=0.029), appearance rash. In addition, a common haplotype PIK3CA gene (P=0.045) (P=0.009). conclusion, genetic variation within its signaling partner might predict EGFR-inhibitor-related
nature.com
sci-hub.se 参考文章(40)
Román Peréz-Soler, Leonard Saltz, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of Clinical Oncology. ,vol. 23, pp. 5235- 5246 ,(2005) , 10.1200/JCO.2005.00.6916
Anna Liza C. Agero, Stephen W. Dusza, Cristiane Benvenuto-Andrade, Klaus J. Busam, Patricia Myskowski, Allan C. Halpern, Dermatologic side effects associated with the epidermal growth factor receptor inhibitors Journal of the American Academy of Dermatology. ,vol. 55, pp. 657- 670 ,(2006) , 10.1016/J.JAAD.2005.10.010
Mario E. Lacouture, Mechanisms of cutaneous toxicities to EGFR inhibitors. Nature Reviews Cancer. ,vol. 6, pp. 803- 812 ,(2006) , 10.1038/NRC1970
T. Moriai, M. S. Kobrin, C. Hope, L. Speck, M. Korc, A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 91, pp. 10217- 10221 ,(1994) , 10.1073/PNAS.91.21.10217
Diletta Bianchini, Akali Jayanth, Yu Jo Chua, David Cunningham, Epidermal Growth Factor Receptor Inhibitor–Related Skin Toxicity: Mechanisms, Treatment, and its Potential Role as a Predictive Marker Clinical Colorectal Cancer. ,vol. 7, pp. 33- 43 ,(2008) , 10.3816/CCC.2008.N.005
V Gregorc, M Hidalgo, A Spreafico, G Cusatis, V Ludovini, RG Ingersoll, S Marsh, SM Steinberg, MG Viganò, D Ghio, E Villa, A Sparreboom, SD Baker, Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib Clinical Pharmacology & Therapeutics. ,vol. 83, pp. 477- 484 ,(2008) , 10.1038/SJ.CLPT.6100320
Amir Harandi, Aisha S. Zaidi, Abigail M. Stocker, Damian A. Laber, Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers Journal of Oncology. ,vol. 2009, pp. 567486- 567486 ,(2009) , 10.1155/2009/567486
Román Pérez-Soler, Abraham Chachoua, Lisa A. Hammond, Eric K. Rowinsky, Mark Huberman, Daniel Karp, James Rigas, Gary M. Clark, Pedro Santabárbara, Philip Bonomi, Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 22, pp. 3238- 3247 ,(2004) , 10.1200/JCO.2004.11.057
Deric L. Wheeler, Emily F. Dunn, Paul M. Harari, Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nature Reviews Clinical Oncology. ,vol. 7, pp. 493- 507 ,(2010) , 10.1038/NRCLINONC.2010.97
Rebecca Suk Heist, David Christiani, EGFR-targeted therapies in lung cancer: predictors of response and toxicity Pharmacogenomics. ,vol. 10, pp. 59- 68 ,(2009) , 10.2217/14622416.10.1.59